Everlywell now offers the FDA-authorized Clairity Breast AI tool for patients to assess breast cancer risk from their mammograms.
Key Details
- 1Everlywell is selling the Clairity Breast mammography AI solution directly to consumers for $249.
- 2Women can upload their mammogram images to the platform for five-year breast cancer risk prediction.
- 3Clairity Breast was authorized by the FDA in 2025.
- 4Everlywell serves approximately 60 million people with various digital health solutions.
- 5The company aims to expand access to preventive breast cancer care through this partnership.
Why It Matters
This move could reshape how patients engage with imaging AI by bypassing traditional physician channels and expanding access to breast cancer risk assessment. It underscores the growing role of consumer-facing AI tools in radiology and the importance of regulatory oversight.
Source
Radiology Business
Related News
•Radiology Business
Sweden Deploys AI as Standalone Second Reader for Mammography
Three Stockholm hospitals will adopt AI to fully replace radiologist second reads in breast cancer screening.
•Radiology Business
BCRF Launches $100M Fund, Invests in AI Mammography Startup Clairity
BCRF unveils a $100M fund, awarding its first investment to AI mammography company Clairity Inc.
•Radiology Business
Rad Partners Wins $1.29M FDA Grant for AI Radiology Report Evaluation Study
Cognita Imaging, part of Rad Partners, has received a $1.29M FDA grant to develop a new framework using large language models (LLMs) to evaluate AI-generated radiology reports.